Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Hematology, Capital Medical University Beijing Friendship Hospital, Beijing, China.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hum Pathol. 2020 Apr;98:1-9. doi: 10.1016/j.humpath.2020.01.005. Epub 2020 Feb 4.
Anaplastic large cell lymphoma (ALCL) is a T-cell neoplasm characterized by uniformly strong CD30 expression and common absence of T-cell markers. Most ALCL cases express CD4, but a small subset of ALCL cases has been reported to express CD8. Little is known about the clinicopathologic and prognostic features of CD8+ ALCL. In this study, CD8 was assessed in 158 patients with systemic ALCL: CD8 was positive in 13 of 67 (19%) ALK+ and 13 of 91 (14%) ALK-negative neoplasms. In ALK+ ALCL, the CD8+ subgroup more often showed a noncommon morphologic pattern (69% vs 13%, P = .0001) and was more often positive for CD2 (100% vs 45%, P = .001), CD3 (92% vs 24%, P = .0001), and CD7 (100% vs. 39%, P = .002), but less frequently positive for CD25 (50% vs. 100%, P = .02). Patients with ALK+ ALCL and CD8+ neoplasms also had a higher relapse rate (82% vs 48%, P = .05) and more often underwent stem cell transplant (73% vs 36%, P = .04). CD8 expression did not correlate with patient overall survival or progression-free survival regardless of ALK status (all P > 0.05). We conclude that CD8+ ALCL cases appear to be biologically different from the more common CD8-negative ALCL cases. Our data suggest that CD8 positivity in ALK+ ALCL helps to identify a subset of patients more prone to relapse or more in need of stem cell transplant during their clinical course, although there was no impact on survival in this cohort.
间变大细胞淋巴瘤（ALCL）是一种 T 细胞肿瘤，其特征为均匀强表达 CD30 和常见的 T 细胞标志物缺失。大多数 ALCL 病例表达 CD4，但已有少量报道称，一小部分 ALCL 病例表达 CD8。对于 CD8+ ALCL 的临床病理和预后特征知之甚少。在这项研究中，对 158 例系统性 ALCL 患者进行了 CD8 评估：ALK+ 的 67 例（19%）和 ALK-的 91 例（14%）肿瘤中有 13 例 CD8 阳性。在 ALK+ ALCL 中，CD8+ 亚组更常表现为非常见形态模式（69%比 13%，P=0.0001），并且更常表达 CD2（100%比 45%，P=0.001）、CD3（92%比 24%，P=0.0001）和 CD7（100%比 39%，P=0.002），但 CD25 表达较少（50%比 100%，P=0.02）。ALK+ ALCL 伴 CD8+ 肿瘤的患者复发率更高（82%比 48%，P=0.05），并且更常接受干细胞移植（73%比 36%，P=0.04）。无论 ALK 状态如何，CD8 表达与患者总生存或无进展生存均无相关性（所有 P>0.05）。我们的结论是，CD8+ ALCL 病例似乎与更为常见的 CD8-ALCL 病例在生物学上有所不同。我们的数据表明，ALK+ ALCL 中的 CD8 阳性有助于识别一组在其临床过程中更容易复发或更需要干细胞移植的患者，尽管在该队列中对生存没有影响。
